EVO 756
Alternative Names: EVO-756; MAS-related G-protein coupled receptor X2 inhibitor - Evommune; MRGPRX2 inhibitor - EvommuneLatest Information Update: 13 Sep 2026
At a glance
- Originator Dermira
- Developer Evommune
- Class Anti-inflammatories; Antiasthmatics; Antimigraines; Antipruritics; Skin disorder therapies; Small molecules
- Mechanism of Action MRGPRX2 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Pruritus
Highest Development Phases
- Phase II Migraine
- Discontinued Asthma; Atopic dermatitis; Chronic urticaria; Interstitial cystitis; Pruritus
Most Recent Events
- 13 Sep 2026 Discontinued - Phase-I for Asthma (unspecified route) (Evommune pipeline, September 2026)
- 13 Sep 2026 Discontinued - Phase-II for Atopic dermatitis in New Zealand (PO) (Evommune pipeline, September 2026)
- 13 Sep 2026 Discontinued - Phase-II for Atopic dermatitis in USA (PO) (Evommune pipeline, September 2026)